Atorvastatin

Generic Name
Atorvastatin
Brand Names
Atorvaliq, Caduet, Lipitor, Lypqozet
Drug Type
Small Molecule
Chemical Formula
C33H35FN2O5
CAS Number
134523-00-5
Unique Ingredient Identifier
A0JWA85V8F
Background

Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylg...

Indication

Atorvastatin is indicated for the treatment of several types of dyslipidemias, including primary hyperlipidemia and mixed dyslipidemia in adults, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, and heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modifications.
...

Associated Conditions
Anginal Pain, Cardiovascular Complications, Cardiovascular Disease (CVD), Coronary Artery Disease (CAD), Coronary artery thrombosis, Dysbetalipoproteinemia, Fredrickson Type III lipidemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hospitalizations, Hypertension, Essential Hypertension, Hypertriglyceridemias, Mixed Dyslipidemias, Mixed Hyperlipidemia, Myocardial Infarction, Non-familial hypercholesterolemia, Nonfatal Myocardial Infarction, Postoperative Thromboembolism, Primary Hypercholesterolemia, Stroke, Thrombosis, Transient Ischemic Attack, Elevation of serum triglyceride levels, Heterozygous familial hyperlipidemia, Non-familial hyperlipidemia, Primary Hyperlipidemia, Revascularization procedures
Associated Therapies
-
Clinical Trials
Related News

LUNAR IIIb Study Comparing Rosuvastatin and Atorvastatin in Subjects With Acute Coronary Syndromes

Phase 3
Completed
Conditions
Acute Coronary Syndromes
First Posted Date
2005-09-22
Last Posted Date
2010-11-19
Lead Sponsor
AstraZeneca
Target Recruit Count
825
Registration Number
NCT00214630
Locations
🇵🇦

Research Site, Panama City, Panama

CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients

First Posted Date
2005-09-21
Last Posted Date
2008-01-08
Lead Sponsor
Nabi Biopharmaceuticals
Target Recruit Count
203
Registration Number
NCT00211939
Locations
🇺🇸

University of Texas Health Sciences Center, San Antonio, Texas, United States

Differences in Atorvastatin Metabolite Ratios as a Diagnostic Tool in Detecting Atorvastatin Induced Myotoxicity

Phase 4
Completed
Conditions
Muscular Diseases
First Posted Date
2005-09-20
Last Posted Date
2012-05-10
Lead Sponsor
Oslo University Hospital
Target Recruit Count
53
Registration Number
NCT00199745
Locations
🇳🇴

Lipidklinikken, Rikshospitalet-Radiumhospitalet HF, Oslo, Norway

A 16 Week Comparative Study of Fenofibrate Versus Ezetimibe as Add-on Therapy to Atorvastatin

Phase 3
Completed
Conditions
Hyperlipidemia
First Posted Date
2005-09-20
Last Posted Date
2007-10-04
Lead Sponsor
Abbott
Target Recruit Count
174
Registration Number
NCT00195793

Phase 2 Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma

Phase 2
Completed
Conditions
Leukemia
Lymphoma, Non-Hodgkin
Interventions
Drug: Atorvastatin
First Posted Date
2005-09-16
Last Posted Date
2017-12-02
Lead Sponsor
Dean Felsher
Target Recruit Count
25
Registration Number
NCT00185731
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

The Effect of Statin Use on Vascular Function in Hypertensive Subjects

Phase 4
Terminated
Conditions
Hypertension
Interventions
Drug: atorvastatin
Other: placebo
First Posted Date
2005-09-16
Last Posted Date
2010-05-28
Lead Sponsor
Johns Hopkins University
Target Recruit Count
24
Registration Number
NCT00181181
Locations
🇺🇸

Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States

The Effects of Atorvastatin on Vulnerable Plaques in Untreated Dyslipidemic Patients.

Not Applicable
Completed
Conditions
Hyperlipidemia
Interventions
Drug: Atorvastatin
First Posted Date
2005-09-15
Last Posted Date
2009-01-05
Lead Sponsor
National Taiwan University Hospital
Target Recruit Count
43
Registration Number
NCT00172419
Locations
🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

Comparing Amlodipine/Atorvastatin Co-Administration To Amlodipine Alone In Patients With Hypertension And Dyslipidemia

Phase 4
Completed
Conditions
Hypertension
Hyperlipidemia
First Posted Date
2005-09-15
Last Posted Date
2021-01-27
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
330
Registration Number
NCT00174330
Locations
🇨🇳

Pfizer Investigational Site, Tianjin, China

Atorvastatin in Myeloma

Phase 1
Conditions
Myeloma
First Posted Date
2005-09-14
Last Posted Date
2006-10-11
Lead Sponsor
Bayside Health
Registration Number
NCT00164086
Locations
🇦🇺

Alfred Hospital, Melbourne, Victoria, Australia

Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells

First Posted Date
2005-09-14
Last Posted Date
2014-09-08
Lead Sponsor
Emory University
Target Recruit Count
36
Registration Number
NCT00166036
Locations
🇺🇸

Emory University Hospital, Atlanta, Georgia, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy